Amivantamab/erlotinib/patritumab-deruxtecan: Acquired drug resistance: 4 case reports.
In: Reactions Weekly, Jg. 1949 (2023-03-25), Heft 1, S. 46-46
serialPeriodical
Zugriff:
Patient 1: A 56-year-old woman, who had metastatic EGFR-mutated lung adenocarcinoma, previously received osimertinib and unspecified platin-doublet chemotherapy. Patient 4: A 66-year-old woman, who had metastatic EGFR-mutated lung adenocarcinoma, previously received unspecified platin-doublet chemotherapy and afatinib. Patient 2: A 66-year-old woman, who had metastatic EGFR-mutated lung adenocarcinoma, previously received unspecified platin-doublet chemotherapy. [Extracted from the article]
Titel: |
Amivantamab/erlotinib/patritumab-deruxtecan: Acquired drug resistance: 4 case reports.
|
---|---|
Zeitschrift: | Reactions Weekly, Jg. 1949 (2023-03-25), Heft 1, S. 46-46 |
Veröffentlichung: | 2023 |
Medientyp: | serialPeriodical |
ISSN: | 0114-9954 (print) |
DOI: | 10.1007/s40278-023-36026-6 |
Schlagwort: |
|
Sonstiges: |
|